http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H03163021-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb66d9373d09efad73c142762f6dfb00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e5edd48190cba3fa70dd3975efd9831
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D267-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D281-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-554
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D281-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D267-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-04
filingDate 1990-08-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7e29738e2d340cdad1fe5bd1c29fbce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1deff904294983e4108e88298c20a8af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2abb80f3f585b9003aa69ea51ca9d5ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6e85e25112fc2871b50973137c00d3a
publicationDate 1991-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H03163021-A
titleOfInvention Pharmaceutical composition for preventing and treating aids including dibenz(b,f)(1,4)oxazepin (and-thiazepin)-11(10 h)-ones or-thiones
abstract PURPOSE: To prepare a pharmaceutical composition useful for prevention and treatment of AIDS by including dibenz[6,f][1,4]oxazepin(and -thiazepin)-11(10H)- ones or -thiones. n CONSTITUTION: The objective composition is obtained by mixing a compound of the formula (X is O or S; Z is O or S; R 1 is H, a 1-6C alkyl, a 2-6C fluoroalkylmethyl having 1 to 3Fs, etc.; R 2 is H, methyl or a halogen; R 3 is H, a 1-4C alkyl, a halogen, etc.; R 4 is H, methyl or a halogen; R 5 is H, a 1-4C alkyl, hydroxyl, etc.) or a salt thereof, and a pharmaceutically acceptable additive, and the objective medical preparation is obtained therefrom by a conventional method. The composition can be formed into a tablet, a capsule, a solution, a suspension, a suppository, etc. The daily dose of the compound of the formula is 10-500mg in oral administration. The compound of the formula is included in 1-50mg in the preparation for the parenteral administration and a preparation containing 0.01-1wt.% active ingredient is preferable in the topical administration. The large majority of the compound of the formula is well known but some thereof are new. n COPYRIGHT: (C)1991,JPO
priorityDate 1989-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458393636
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458397310
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13781592
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419792809

Total number of triples: 33.